Suchergebnisse - "Corso, Alessandro"

PubPharm (35)

1

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

2

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

3

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse

enthalten in: British journal of haematology | 2020

von Montefusco, V. | Corso, A. | Galli, M. | +13

4

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Richardson, P. | Oriol, A. | Beksac, M. | +123

CommentIn: Lancet Oncol. 2019 Jun;20(6):743-744. - PMID 31097404

5

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

enthalten in: Annals of hematology | 2019

von Musto, P. | Simeon, V. | Cascavilla, N. | +25

6

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

enthalten in: Annals of hematology | 2018

von Musto, P. | Simeon, V. | Cascavilla, N. | +25

7

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

enthalten in: Annals of hematology | 2018

von Musto, P. | Simeon, V. | Cascavilla, N. | +25

8

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

enthalten in: Annals of hematology | 2018

von Musto, P. | Simeon, V. | Cascavilla, N. | +25

9

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2018

von Mohty, M. | Terpos, E. | Mateos, M. | +130

10

The advantages of switch to subcutaneous bortezomib in the real life

enthalten in: Leukemia & lymphoma | 2018

von Mangiacavalli, S. | Cocito, F. | Ferretti, V. | +3